View Clinical Trial (Medical Research Study)
Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)
| City: |
|
Detroit |
| State: |
|
Michigan |
| Zip Code: |
|
48201 |
| Conditions: |
|
Hypertension |
| Purpose: |
|
To determine whether impedance cardiography (ICG) parameters can predict favorable or
unfavorable blood pressure (BP) response and time to BP control prior to initiation or
intensification of specific antihypertensive drug classes and drug combinations, independent
of initial BP levels.
|
| Study Summary: |
|
- Patients with higher vascular resistance index and/or lower arterial compliance index
will lower BP faster and to a greater degree overall when receiving vasodilating agents
- such as ACEI's, ARB's, dihydropyridine CCB's, direct vasodilators, and central alpha
agonists.
- Patients with an elevated cardiac index will lower BP faster and to a greater degree
overall when receiving agents that reduce contractility, heart rate, or blood volume -
such as beta blockers, non-dihydropyridine CCB's, and other agents that are known to
reduce cardiac index.
- Patients with an elevated thoracic fluid content or lower orthostatic change in
thoracic fluid content will lower BP faster and to a greater degree overall when
receiving diuretics (thiazide, loop, potassium sparing), however - one of these agents
will emerge as a superior alternative to reduce BP in patients with high thoracic fluid
content / low orthostatic change in thoracic fluid content.
|
| Criteria: |
|
Inclusion Criteria:
- > 18 years of age
- Able to provide written consent
- Meet JNC definition of hypertension
- Lab results with 6 months for: serum creatinine, urine albumin/creatinine ratio, and
at least one of the following: serum glucose, or glycated hemoglobin, or hemoglobin
A1C
Exclusion Criteria:
- Active cardiovascular disease (unstable angina, stage C or D heart failure,
uncontrolled superventricular arrhythmia, hx of ventricular arrhythmia, stroke or TIA
within 6 months, ACS within 6 months)
- Implantation of activated ventricular pacemaker
- Known hypersensitivity or allergy to sensor gel or adhesives
- Skin lesions prohibiting sensor placement
|
| NCT ID: |
|
NCT00913094 |
| Primary Contact: |
|
Principal Investigator
John M Flack, MD
Wayne State University, and Detroit Medical Center
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Detroit, Michigan 48201
United States
Mary Maysura
Phone: 313-745-2378
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|